Travellers between Singapore and South Korea can now have a travel medicine pass, following a strategic partnership between Raffles Hospital – a fully-owned subsidiary of Raffles Medical Group – and Myongji Hospital.
With this, pass holders will have a suite of medical services and a seamless booking of the pre-departure and on-arrival Covid-19 testing.
They will also receive priority access to treatments at medical facilities operated by either hospital, should they have a medical emergency in the course of their travel.
Travellers leaving Singapore can sign up for the pass by booking their pre-departure Covid-19 test through the Raffles Medical Group’s RafflesConnect app.
The app also allows travellers to pre-book their on-arrival Covid-19 tests at the Incheon International Airport. They can subsequently fulfill Covid-19 tests at the designated Raffles Medical clinics in Singapore, once they return.
“As overseas travel progressively opens up, we are delighted to partner Myongji Hospital to create a safe and seamless international travel experience for many,” says Loo Choon Yong, executive chairman of Raffles Medical Group.
See also: New Key Summary 123
"Exchanges and alliances between Myongji Hospital and Raffle Hospital these past 17 years have been expanded to 'national partnership' in the healthcare sector as a representative medical institution in both countries,’ quips Lee Wang-jun, chairman of Myongji Hospital.
"With this partnership agreement, we will enable a safe travel bubble in the era of Covid-19, and support stable and continuous management of health emergencies that may occur while travelling in Korea, as well as one-stop inspections for travellers," adds Lee.
Myongji Hospital operates two general hospitals, a nursing hospital and two clinics.
See also: Resourse Library Event
In addition to operating a Covid-19 testing centre at the Incheon International Airport, it has a treatment ward for patients with severe symptoms of Covid-19 as well as a national isolation ward. It also treats patients with mild symptoms of Covid-19 through its life treatment centre and home treatment centre.
Shares in Raffles Medical Group closed down 2 cents or 1.5% at $1.31 on Dec 13.
Cover image: file photo
